Stroke is one of the most common, and damaging, neurological afflictions. Stroke causes widespread and variable chronic effects, due to the limited regenerative ability of the adult brain. Altered gene expression induces neuronal changes necessary for plasticity-dependent recovery, effects which can be enhanced by growth hormone-based pharmaceuticals. These processes are driven by alterations in the informational capacity of the genome – changes driven by epigenetic regulators. Following experimental strokes, and treatment with EGF and EPO, this study shows that two epigenetic regulatory mechanisms, DNA methylation and microRNA regulation, are significantly altered, both in treated and untreated animals. Specifically, treatment induces a net global suppression of miRNA activity, which appears to modify the physical behaviour of neurons in domains ranging from plasticity and memory formation, growth and replication, and potentially even to neurological disease signalling. The confirmation of epigenetic alterations following a stroke indicates a future role for epigenetic neuro-pharmacology in stroke management. / x, [99] leaves : ill. (some col.) ; 29 cm

Indiana University-Purdue University Indianapolis (IUPUI) / Histone acetylation has been linked to developmental changes in gene expression and is a validated drug target of apicomplexan parasites, but little is known about the roles of individual histone modifying enzymes and how they are recruited to target genes. The protozoan parasite Toxoplasma gondii (phylum Apicomplexa) is unusual among invertebrates in possessing two GCN5-family lysine acetyltransferases (KATs). While GCN5a is required for gene expression in response to alkaline stress, this KAT is dispensable for parasite proliferation in normal culture conditions. In contrast, GCN5b cannot be disrupted, suggesting it is essential for Toxoplasma viability. To further explore the function of GCN5b, we generated clonal parasites expressing an inducible HA-tagged form of GCN5b containing a point mutation that ablates enzymatic activity (E703G). Stabilization of this dominant-negative form of GCN5b was mediated through ligand-binding to a destabilization domain (dd) fused to the protein. Induced accumulation of the ddHAGCN5b(E703G) protein led to a rapid arrest in parasite replication. Growth arrest was accompanied by a decrease in histone H3 acetylation at specific lysine residues as well as reduced expression of GCN5b target genes in GCN5b(E703G) parasites, which were identified using chromatin immunoprecipitation coupled with microarray hybridization (ChIP-chip). We also demonstrate that GCN5b interacts with AP2-domain proteins, which are plant-like transcription factors in Apicomplexa. The interactions between GCN5b, AP2IX-7, and AP2X-8 were confirmed by reciprocal co-immunoprecipitation and revealed a “core complex” that includes the co-activator ADA2-A, TFIID subunits, LEO1 polymerase-associated factor (Paf1) subunit, and RRM proteins. The dominant-negative phenotype of ddHAGCN5b(E703G) parasites, considered with the proteomics and ChIP-chip data, indicate that GCN5b plays a central role in transcriptional and chromatin remodeling complexes. We conclude that GCN5b has a non-redundant and indispensable role in regulating gene expression required during the Toxoplasma lytic cycle.